The Medical Letter on Drugs and Therapeutics
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
Download PDF:   US English
 Select a term to see related articles  acetylsalicylic acid   Anticoagulants   apixaban   Arixtra   Aspirin   Atrial fibrillation   Coumadin   Dabigatran   Deep vein thrombosis   DOAC   edoxaban   Eliquis   Fondaparinux   Heparin   noac   NSAIDs   Pradaxa   Rifampin   Rivaroxaban   Savaysa   SSRIS   Venous thromboembolism   Warfarin   Xarelto 

The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.

STANDARD TREATMENT — Acute VTE (deep vein thrombosis or pulmonary embolism) is usually treated initially with a parenteral anticoagulant such as unfractionated heparin, low molecular weight heparin (LMWH), or fondaparinux (Arixtra, and generics). Warfarin (Coumadin, and others) is started on the same day as parenteral therapy and titrated to an INR of 2-3. After ≥5 days, the parenteral anticoagulant is stopped and warfarin is continued as monotherapy. The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) all appear to be effective and safe alternatives to warfarin for treatment of acute VTE, but data in elderly patients and those with significant comorbidities are limited. Treatment of acute VTE usually continues for at least 3 months.1,2

In patients with nonvalvular atrial fibrillation, dabigatran, rivaroxaban, and apixaban all appear to be at least as effective as warfarin in preventing stroke, with significantly lower rates of intracranial bleeding and hemorrhagic stroke.3-5 Patients with atrial fibrillation associated with a mechanical valve or moderate to severe mitral stenosis should take warfarin.

WARFARIN vs. NEW ORAL ANTICOAGULANTS — Use of warfarin is complicated by the need for frequent monitoring of the INR, dietary restrictions, and concerns about its interactions with many other drugs. The new oral anticoagulants do not require routine INR-type monitoring, have no dietary restrictions, and may have fewer drug interactions than warfarin, but there is no fixed method for determining the extent of their anticoagulant effect, they have short half-lives that increase the risk of thrombosis with missed doses, and they are not recommended for use in patients with end-stage renal disease. No established antidote is currently available for these new drugs, but their anticoagulant effect may be reversed by prothrombin complex concentrate, and clinical studies of more specific reversal agents are in progress.5-7

PHARMACOKINETICS — Because of its high renal clearance, blood levels of edoxaban are higher in patients with decreased renal function. A pharmacokinetic study summarized in the package insert found that systemic exposure to edoxaban was >70% higher among patients with a CrCl ≤50 mL/min than among those with a CrCl ≥80 mL/min.

CLINICAL STUDIES — Edoxaban 60 mg/day (or 30 mg/day in patients with CrCl 30-50 mL/min, weight ≤60 kg, or concomitant use of P-glycoprotein inhibitors) has been compared to warfarin (INR 2-3) for both VTE and atrial fibrillation.8,9

Venous Thromboembolism – In a randomized, double-blind, 12-month noninferiority trial (Hokusai-VTE) in 8240 patients with acute VTE first treated with unfractionated heparin or LMWH, edoxaban was noninferior to warfarin in preventing symptomatic recurrent VTE (the primary endpoint), which occurred in 3.2% of patients taking edoxaban and 3.5% of those on warfarin. Patients taking edoxaban had a significantly lower rate of major or clinically relevant non-major bleeding (8.5% vs. 10.3%). There were no fatal intracranial bleeds in the edoxaban group compared to six in warfarin-treated patients. More than 90% of the study population had a CrCl >50 mL/min, and renal function had no effect on the incidence of the primary endpoint in patients taking edoxaban.8

Atrial Fibrillation – In a randomized, double-blind trial (ENGAGE AF-TIMI 48) in 21,105 patients with atrial fibrillation and a CHADS2 score ≥2, stroke or systemic embolism (the primary endpoint) occurred after a median follow-up of 2.8 years at a significantly lower annual rate with edoxaban than with warfarin (1.18% vs. 1.50%). Edoxaban use was also associated with significantly reduced annual rates of major bleeding (2.75% vs. 3.43%), intracranial bleeding (0.39% vs. 0.85%), and cardiovascular death (2.74% vs. 3.17%).9

Among patients with CrCl >95 mL/min, however, the rate of ischemic stroke was significantly higher with edoxaban (0.9%) than with warfarin (0.4%).10

ADVERSE EFFECTS — The most common adverse effect of edoxaban in clinical trials was bleeding. Edoxaban has no established antidote to reverse its anticoagulant effect, which persists for about 24 hours after the last dose, and it is not dialyzable. Epidural or spinal hematomas resulting in permanent paralysis could occur in patients taking the drug who require neuraxial anesthesia or spinal puncture.

PREGNANCY — Edoxaban is classified as category C (no teratogenic effects in animals, no adequate studies in women) for use during pregnancy.

DRUG INTERACTIONS — Concomitant use of edoxaban with other drugs that interfere with hemostasis, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs), increases the risk of bleeding.

Edoxaban is a substrate of P-glycoprotein (P-gp) and should not be used concomitantly with the P-gp inducer rifampin. Concomitant use of P-gp inhibitors may increase serum concentrations of edoxaban.11

DOSAGE ADJUSTMENTS – Dosage adjustments for edoxaban and the other oral anticoagulants are listed in Table 2.

Subgroup analyses of the Hokusai-VTE trial, described in FDA review documents, found that patients treated for VTE with edoxaban 30 mg/day because they weighed ≤60 kg had similar efficacy and safety outcomes as those receiving 60 mg/day who did not require a dosage adjustment. An analysis of patients taking edoxaban 30 mg/day solely because of concomitant P-gp inhibitor use was not possible because this subgroup constituted <1% of the study population. Current product labeling recommends that patients with VTE who are receiving a P-gp inhibitor specified in the Hokusai-VTE trial protocol (verapamil or quinidine for chronic use, or azithromycin, clarithromycin, erythromycin, ketoconazole, or itraconazole for acute use) take 30 mg/day of edoxaban.

Subgroup analyses of the ENGAGE AF-TIMI 48 trial, described in FDA review documents, found that patients with atrial fibrillation taking 30 mg/day of edoxaban because they weighed ≤60 kg or were taking a P-gp inhibitor had a smaller reduction in the incidence of the primary endpoint than those receiving 60 mg/day who did not require a dosage adjustment. Consequently, no dose reduction is recommended for patients with atrial fibrillation based on body weight or concomitant use of a P-gp inhibitor. Edoxaban should not be used for treatment of atrial fibrillation in patients with a CrCl >95 mL/min.

CONCLUSION — Edoxaban (Savaysa) appears to be similar in efficacy to warfarin in treating acute venous thromboembolism. For prevention of stroke in patients with nonvalvular atrial fibrillation, edoxaban was at least as effective as warfarin and caused less bleeding, but in patients with a CrCl >95 mL/min, the incidence of ischemic stroke was higher with edoxaban, and the drug should not be used in such patients. How edoxaban compares in efficacy and safety with dabigatran (Pradaxa), rivaroxaban (Xarelto), or apixaban (Eliquis) remains to be determined.

  1. C Kearon et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 suppl):e419S.
  2. New oral anticoagulants for acute venous thromboembolism. Med Lett Drugs Ther 2014; 56:3.
  3. CT January et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
  4. AJ Camm et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719.
  5. Treatment of atrial fibrillation. Med Lett Drugs Ther 2014; 56:53.
  6. Antithrombotic drugs. Med Lett Drugs Ther 2014; 56:103.
  7. WI Gonsalves et al. Management of bleeding complications in patients on new oral anticoagulants. J Hematol Transfus 2014; 2:1015.
  8. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.
  9. RP Giugliano et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093.
  10. MJ Blank and T-Y McDowell. Clinical review: edoxaban. NDA 206316. Available at: Accessed March 19, 2015.
  11. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.